Meningococcal meningitis in Spain in the Horizon 2030: A position paper.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sociedad Española de Quimioterapia Country of Publication: Spain NLM ID: 9108821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1988-9518 (Electronic) Linking ISSN: 02143429 NLM ISO Abbreviation: Rev Esp Quimioter Subsets: MEDLINE
    • Publication Information:
      Publication: [Barcelona] : Sociedad Española de Quimioterapia
      Original Publication: Barcelona : J.R. Prous, S.A., [1988-
    • Subject Terms:
      Meningitis, Meningococcal*/epidemiology ; Meningitis, Meningococcal*/prevention & control; Humans ; Spain/epidemiology ; Incidence ; Meningococcal Vaccines ; Neisseria meningitidis ; Child ; Child, Preschool ; Adolescent
    • Abstract:
      Meningococcal meningitis (MM) and invasive meningococcal disease remain a major public health problem that generates enormous public alarm. It is caused by Neisseria meningitidis, a Gram-negative diplococcus with an enormous capacity for acute and rapidly progressive disease, both episodic and epidemic in nature, with early diagnosis and treatment playing a major role. It occurs at any age, but is most common in children under 5 years of age followed by adolescents. Although most cases occur in healthy people, the incidence is higher in certain risk groups. Despite advances in reducing the incidence, it is estimated that in 2017 there were around 5 million new cases of MM worldwide, causing approximately 290,000 deaths and a cumulative loss of about 20,000,000 years of healthy life. In Spain, in the 2021/22 season, 108 microbiologically confirmed cases of MM were reported, corresponding to an incidence rate of 0.23 cases per 100,000 inhabitants. This is a curable and, above all, vaccine-preventable disease, for which the World Health Organisation has drawn up a roadmap with the aim of reducing mortality and sequelae by 2030. For all these reasons, the Illustrious Official College of Physicians of Madrid (ICOMEM) and the Medical Associations of 8 other provinces of Spain, have prepared this opinion document on the situation of MM in Spain and the resources and preparation for the fight against it in our country. The COVID-19 and Emerging Pathogens Committee of ICOMEM has invited experts in the field to participate in the elaboration of this document.
      (©The Author 2024. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).)
    • References:
      Pathog Glob Health. 2022 Mar;116(2):85-98. (PMID: 34569453)
      Lancet Neurol. 2023 Aug;22(8):685-711. (PMID: 37479374)
      EClinicalMedicine. 2022 Feb 14;44:101275. (PMID: 35198914)
      N Engl J Med. 2006 Jan 5;354(1):44-53. (PMID: 16394301)
      Emergencias. 2022 Dec;34(6):471-473. (PMID: 36625699)
      An Pediatr (Engl Ed). 2024 May;100(5):e28-e30. (PMID: 38582645)
      Lancet Infect Dis. 2022 Jul;22(7):1021-1029. (PMID: 35427490)
      Clin Infect Dis. 2021 Aug 2;73(3):e609-e619. (PMID: 33212510)
      Enferm Infecc Microbiol Clin (Engl Ed). 2021 Oct;39(8):403-410. (PMID: 34620475)
      Vaccines (Basel). 2022 Apr 12;10(4):. (PMID: 35455341)
      Clin Infect Dis. 2023 Feb 8;76(3):e1341-e1349. (PMID: 35642527)
      Epidemiol Infect. 2023 Mar 06;151:e57. (PMID: 37052295)
      Nature. 2010 Nov 11;468(7321):143. (PMID: 21068797)
      Science. 2008 Jun 27;320(5884):1710-5. (PMID: 18583588)
      Enferm Infecc Microbiol Clin. 2013 Mar;31(3):173-80. (PMID: 22409951)
      Clin Infect Dis. 2021 Oct 5;73(7):e1661-e1668. (PMID: 32845996)
      Nat Commun. 2023 Nov 24;14(1):7706. (PMID: 38001084)
      Enferm Infecc Microbiol Clin (Engl Ed). 2020 Apr 25;:. (PMID: 32345489)
      Vaccines (Basel). 2019 Jan 05;7(1):. (PMID: 30621260)
      NPJ Vaccines. 2021 Oct 29;6(1):130. (PMID: 34716336)
      Infection. 2024 Feb;52(1):165-172. (PMID: 37515691)
      Methods Mol Biol. 2019;1969:1-16. (PMID: 30877666)
      Emergencias. 2023 Feb;35(1):53-64. (PMID: 36756917)
      PLoS One. 2021 Nov 29;16(11):e0260677. (PMID: 34843604)
      Rev Esp Quimioter. 2018 Feb;31(1):1-12. (PMID: 29390599)
      BMC Public Health. 2022 Feb 23;22(1):380. (PMID: 35197024)
      Expert Rev Vaccines. 2009 Jul;8(7):851-61. (PMID: 19538112)
      Emergencias. 2022 Apr;34(2):139-140. (PMID: 35275465)
      N Engl J Med. 2020 Jan 23;382(4):318-327. (PMID: 31971677)
      Nat Rev Microbiol. 2020 Feb;18(2):84-96. (PMID: 31705134)
      Enferm Infecc Microbiol Clin (Engl Ed). 2022 Jan;40(1):1-4. (PMID: 34991847)
      Lancet Infect Dis. 2022 Jul;22(7):1011-1020. (PMID: 35427492)
    • Contributed Indexing:
      Keywords: Neisseria meningitidis; antimicrobial treatment; chemoprophylaxis; epidemicst; meningitis; meningococcus; prevention; vaccines
    • Accession Number:
      0 (Meningococcal Vaccines)
    • Publication Date:
      Date Created: 20240322 Date Completed: 20240702 Latest Revision: 20240711
    • Publication Date:
      20240711
    • Accession Number:
      PMC11231484
    • Accession Number:
      10.37201/req/023.2024
    • Accession Number:
      38515374